Works matching AU Kim, Sang-we

Results: 63
    1
    2
    3

    Real-world outcomes of anti-PD1 antibodies in platinum-refractory, PD-L1-positive recurrent and/or metastatic non-small cell lung cancer, and its potential practical predictors: first report from Korean Cancer Study Group LU19-05.

    Published in:
    Journal of Cancer Research & Clinical Oncology, 2021, v. 147, n. 8, p. 2459, doi. 10.1007/s00432-021-03527-4
    By:
    • Park, Ji Hyun;
    • You, Gun Lyung;
    • Ahn, Myung-Ju;
    • Kim, Sang-We;
    • Hong, Min Hee;
    • Han, Ji-Youn;
    • Ock, Chan-Young;
    • Lee, Jong-Seok;
    • Oh, In Jae;
    • Lee, Shin Yup;
    • Kim, Cheol Hyeon;
    • Min, Young Joo;
    • Choi, Yoon Hee;
    • Ryu, Jeong-Seon;
    • Park, Sun Hyo;
    • Ahn, Hee Kyung;
    • Shim, Byoung-Yong;
    • Lee, Ki Hyeong;
    • Lee, Sung Yong;
    • Kim, Jin-Soo
    Publication type:
    Article
    4
    5

    First-line afatinib vs gefitinib for patients with EGFR mutation-positive NSCLC (LUX-Lung 7): impact of afatinib dose adjustment and analysis of mode of initial progression for patients who continued treatment beyond progression.

    Published in:
    Journal of Cancer Research & Clinical Oncology, 2019, v. 145, n. 6, p. 1569, doi. 10.1007/s00432-019-02862-x
    By:
    • Schuler, Martin;
    • Tan, Eng-Huat;
    • O'Byrne, Kenneth;
    • Zhang, Li;
    • Boyer, Michael;
    • Mok, Tony;
    • Hirsh, Vera;
    • Yang, James Chih-Hsin;
    • Lee, Ki Hyeong;
    • Lu, Shun;
    • Shi, Yuankai;
    • Kim, Sang-We;
    • Laskin, Janessa;
    • Kim, Dong-Wan;
    • Arvis, Catherine Dubos;
    • Kölbeck, Karl;
    • Massey, Dan;
    • Märten, Angela;
    • Paz-Ares, Luis;
    • Park, Keunchil
    Publication type:
    Article
    6
    7
    8
    9
    10

    Ramosetron Versus Ondansetron in Combination With Aprepitant and Dexamethasone for the Prevention of Highly Emetogenic Chemotherapy-Induced Nausea and Vomiting: A Multicenter, Randomized Phase III Trial, KCSG PC10-21.

    Published in:
    Oncologist, 2015, v. 20, n. 12, p. 1440, doi. 10.1634/theoncologist.2015-0128
    By:
    • Kim, Hyo Jung;
    • Shin, Sang Won;
    • Song, Eun‐Kee;
    • Lee, Na‐Ri;
    • Kim, Jun Suk;
    • Ahn, Jin Seok;
    • Yun, Hwan‐Jung;
    • Cho, Yo‐Han;
    • Park, Keon Uk;
    • Kim, Si‐Young;
    • Jang, Joung Soon;
    • Kim, Sang‐We;
    • Lee, Hyun Woo;
    • Lee, Se Ryeon;
    • Kim, Yang Soo;
    • Lee, Soon Nam;
    • Ko, Yoon Ho;
    • Kim, Hwa Jung;
    • Kang, Jin‐Hyoung
    Publication type:
    Article
    11
    12

    The Survival and Financial Benefit of Investigator-Initiated Trials Conducted by Korean Cancer Study Group.

    Published in:
    Cancer Research & Treatment, 2025, v. 57, n. 1, p. 39, doi. 10.4143/crt.2024.421
    By:
    • Kim, Bum Jun;
    • Maeng, Chi Hoon;
    • Keam, Bhumsuk;
    • Im, Young-Hyuck;
    • Ro, Jungsil;
    • Jung, Kyung Hae;
    • Im, Seock-Ah;
    • Kim, Tae Won;
    • Lee, Jae Lyun;
    • Heo, Dae Seog;
    • Kim, Sang-We;
    • Park, Keunchil;
    • Ahn, Myung-Ju;
    • Cho, Byoung Chul;
    • Kim, Hoon-Kyo;
    • Kang, Yoon-Koo;
    • Cho, Jae Yong;
    • Yun, Hwan Jung;
    • Nam, Byung-Ho;
    • Zang, Dae Young
    Publication type:
    Article
    13

    Impact of Patient Sex on Adverse Events and Unscheduled Utilization of Medical Services in Cancer Patients Undergoing Adjuvant Chemotherapy: A Multicenter Retrospective Cohort Study.

    Published in:
    Cancer Research & Treatment, 2024, v. 56, n. 2, p. 404, doi. 10.4143/crt.2023.784
    By:
    • Choi, Songji;
    • Seo, Seyoung;
    • Lee, Ju Hyun;
    • Suh, Koung Jin;
    • Kim, Ji-Won;
    • Kim, Jin Won;
    • Kim, Se Hyun;
    • Kim, Yu Jung;
    • Lee, Keun-Wook;
    • Kim, Jwa Hoon;
    • Kim, Tae Won;
    • Hong, Yong Sang;
    • Kim, Sun Young;
    • Kim, Jeong Eun;
    • Kim, Sang-We;
    • Lee, Dae Ho;
    • Lee, Jae Cheol;
    • Choi, Chang-Min;
    • Yoon, Shinkyo;
    • Koh, Su-Jin
    Publication type:
    Article
    14
    15
    16
    17
    18
    19

    Activation of the AXL kinase causes resistance to EGFR-targeted therapy in lung cancer.

    Published in:
    Nature Genetics, 2012, v. 44, n. 8, p. 852, doi. 10.1038/ng.2330
    By:
    • Zhang, Zhenfeng;
    • Lee, Jae Cheol;
    • Lin, Luping;
    • Olivas, Victor;
    • Au, Valerie;
    • LaFramboise, Thomas;
    • Abdel-Rahman, Mohamed;
    • Wang, Xiaoqi;
    • Levine, Alan D;
    • Rho, Jin Kyung;
    • Choi, Yun Jung;
    • Choi, Chang-Min;
    • Kim, Sang-We;
    • Jang, Se Jin;
    • Park, Young Soo;
    • Kim, Woo Sung;
    • Lee, Dae Ho;
    • Lee, Jung-Shin;
    • Miller, Vincent A;
    • Arcila, Maria
    Publication type:
    Article
    20
    21
    22

    Pooled safety analysis and management of sotorasib-related adverse events in KRAS G12C-mutated advanced non-small cell lung cancer.

    Published in:
    Oncologist, 2025, v. 30, n. 1, p. 1, doi. 10.1093/oncolo/oyae356
    By:
    • Skoulidis, Ferdinandos;
    • Li, Bob T;
    • Hochmair, Maximilian;
    • Govindan, Ramaswamy;
    • Vincent, Mark;
    • Wekken, Anthonie J van der;
    • Aransay, Noemi Reguart;
    • O'Byrne, Kenneth J;
    • Girard, Nicolas;
    • Griesinger, Frank;
    • Nishio, Makoto;
    • Häfliger, Simon;
    • Lindsay, Colin;
    • Reinmuth, Niels;
    • Paulus, Astrid;
    • Papakotoulas, Pavlos;
    • Kim, Sang-We;
    • Ferreira, Carlos Gil;
    • Pasello, Giulia;
    • Duruisseaux, Michael
    Publication type:
    Article
    23
    24
    25
    26
    27
    28

    Correlation of hematopoietic progenitor cell count determined by the SE-9000™ automated hematology analyzer with CD34<sup>+</sup> cell count by flow cytometry in leukapheresis products.

    Published in:
    American Journal of Hematology, 2001, v. 67, n. 1, p. 42, doi. 10.1002/ajh.1074
    By:
    • Park, Keon Uk;
    • Kim, Sang Hee;
    • Suh, Cheolwon;
    • Kim, Shin;
    • Lee, Sun Jong;
    • Park, Jung Sun;
    • Cho, Hwa Jung;
    • Kim, Kang Wook;
    • Lee, Keehyun;
    • Kim, Hyo Jung;
    • Park, Jinny;
    • Joo Min, Young;
    • Kim, Jeong Gyoon;
    • Kim, Taewon;
    • Lee, Je Hwan;
    • Kim, Sung Bae;
    • Kim, Sang We;
    • Lee, Kyoo Hyung;
    • Lee, Jung Shin;
    • Kim, Woo Kun
    Publication type:
    Article
    29
    30

    The impact of systematic assessment for adverse events on unscheduled hospital utilization in patients receiving neoadjuvant or adjuvant chemotherapy: A retrospective multicenter study.

    Published in:
    Cancer Medicine, 2022, v. 11, n. 3, p. 705, doi. 10.1002/cam4.4476
    By:
    • Kim, Jwa Hoon;
    • Seo, Seyoung;
    • Kim, Jee Hyun;
    • Koh, Su‐Jin;
    • Ahn, Yongchel;
    • Jung, Kyung Hae;
    • Ahn, Jin‐Hee;
    • Kim, Sung‐Bae;
    • Kim, Tae Won;
    • Hong, Yong Sang;
    • Kim, Sun Young;
    • Kim, Jeong Eun;
    • Kim, Sang‐We;
    • Lee, Dae Ho;
    • Lee, Jae Cheol;
    • Choi, Chang‐Min;
    • Yoon, Shinkyo;
    • Jeong, Jae Ho;
    • Kim, Hwa Jung;
    • Suh, Koung Jin
    Publication type:
    Article
    31
    32
    33
    34

    Gefitinib versus pemetrexed as second-line treatment in patients with nonsmall cell lung cancer previously treated with platinum-based chemotherapy (KCSG-LU08-01).

    Published in:
    Cancer (0008543X), 2012, v. 118, n. 24, p. 6234, doi. 10.1002/cncr.27630
    By:
    • Sun, Jong-Mu;
    • Lee, Ki Hyeong;
    • Kim, Sang-we;
    • Lee, Dae Ho;
    • Min, Young Joo;
    • Yun, Hwan Jung;
    • Kim, Hoon Kyo;
    • Song, Hong Suk;
    • Kim, Yeul Hong;
    • Kim, Bong-Seog;
    • Hwang, In Gyu;
    • Lee, Keehyun;
    • Jo, Sook Jung;
    • Lee, Jae Won;
    • Ahn, Jin Seok;
    • Park, Keunchil;
    • Ahn, Myung-Ju
    Publication type:
    Article
    35

    The NHance ® Mutation-Equipped Anti-MET Antibody ARGX-111 Displays Increased Tissue Penetration and Anti-Tumor Activity in Advanced Cancer Patients.

    Published in:
    Biomedicines, 2021, v. 9, n. 6, p. 665, doi. 10.3390/biomedicines9060665
    By:
    • Aftimos, Philippe;
    • Rolfo, Christian;
    • Rottey, Sylvie;
    • Barthélémy, Philippe;
    • Borg, Christophe;
    • Park, Keunchil;
    • Oh, Do-Youn;
    • Kim, Sang-We;
    • De Jonge, Natalie;
    • Hanssens, Valérie;
    • Zwanenpoel, Karen;
    • Molthoff, Carla;
    • Vugts, Daniëlle;
    • Dreier, Torsten;
    • Verheesen, Peter;
    • van Dongen, Guus A.M.S.;
    • Jacobs, Julie;
    • Van Rompaey, Luc;
    • Hultberg, Anna;
    • Michieli, Paolo
    Publication type:
    Article
    36
    37

    Epidermal growth factor receptor mutation analysis in tissue and plasma from the AURA3 trial: Osimertinib versus platinum-pemetrexed for T790M mutation-positive advanced non-small cell lung cancer.

    Published in:
    2020
    By:
    • Papadimitrakopoulou, Vassiliki A.;
    • Han, Ji‐Youn;
    • Ahn, Myung‐Ju;
    • Ramalingam, Suresh S.;
    • Delmonte, Angelo;
    • Hsia, Te‐Chun;
    • Laskin, Janessa;
    • Kim, Sang‐We;
    • He, Yong;
    • Tsai, Chun‐Ming;
    • Hida, Toyoaki;
    • Maemondo, Makoto;
    • Kato, Terufumi;
    • Jenkins, Suzanne;
    • Patel, Sabina;
    • Huang, Xiangning;
    • Laus, Gianluca;
    • Markovets, Aleksandra;
    • Thress, Kenneth S.;
    • Wu, Yi‐Long
    Publication type:
    journal article
    38

    Biomarker role of thyroid irAE and PD-L1 positivity in predicting PD-1 blockade efficacy in patients with non-small cell lung cancer.

    Published in:
    Cancer Immunology, Immunotherapy, 2024, v. 73, n. 12, p. 1, doi. 10.1007/s00262-024-03852-w
    By:
    • Kim, Hye In;
    • Kim, Won Gu;
    • Kim, Mijin;
    • Ko, Nak Gyeong;
    • Jin, Mihyeon;
    • Jung, Hyun Ae;
    • Sun, Jong-Mu;
    • Ahn, Jin Seok;
    • Ahn, Myung-Ju;
    • Choi, Yoon-La;
    • Jeon, Min Ji;
    • Kim, Tae Yong;
    • Kim, Won Bae;
    • Kim, Sang-We;
    • Lee, Dae Ho;
    • Jang, Se Jin;
    • Kim, Sun Wook;
    • Chung, Jae Hoon;
    • Kim, Tae Hyuk;
    • Lee, Se-Hoon
    Publication type:
    Article
    39

    Biomarker role of thyroid irAE and PD-L1 positivity in predicting PD-1 blockade efficacy in patients with non-small cell lung cancer.

    Published in:
    Cancer Immunology, Immunotherapy, 2024, v. 73, n. 12, p. 1, doi. 10.1007/s00262-024-03852-w
    By:
    • Kim, Hye In;
    • Kim, Won Gu;
    • Kim, Mijin;
    • Ko, Nak Gyeong;
    • Jin, Mihyeon;
    • Jung, Hyun Ae;
    • Sun, Jong-Mu;
    • Ahn, Jin Seok;
    • Ahn, Myung-Ju;
    • Choi, Yoon-La;
    • Jeon, Min Ji;
    • Kim, Tae Yong;
    • Kim, Won Bae;
    • Kim, Sang-We;
    • Lee, Dae Ho;
    • Jang, Se Jin;
    • Kim, Sun Wook;
    • Chung, Jae Hoon;
    • Kim, Tae Hyuk;
    • Lee, Se-Hoon
    Publication type:
    Article
    40

    First-in-human study of oleclumab, a potent, selective anti-CD73 monoclonal antibody, alone or in combination with durvalumab in patients with advanced solid tumors.

    Published in:
    Cancer Immunology, Immunotherapy, 2023, v. 72, n. 7, p. 2443, doi. 10.1007/s00262-023-03430-6
    By:
    • Bendell, Johanna;
    • LoRusso, Patricia;
    • Overman, Michael;
    • Noonan, Anne M.;
    • Kim, Dong-Wan;
    • Strickler, John H.;
    • Kim, Sang-We;
    • Clarke, Stephen;
    • George, Thomas J.;
    • Grimison, Peter S.;
    • Barve, Minal;
    • Amin, Manik;
    • Desai, Jayesh;
    • Wise-Draper, Trisha;
    • Eck, Steven;
    • Jiang, Yu;
    • Khan, Anis A.;
    • Wu, Yuling;
    • Martin, Philip;
    • Cooper, Zachary A.
    Publication type:
    Article
    41
    42
    43

    Phase II evaluation of LY2603618, a first-generation CHK1 inhibitor, in combination with pemetrexed in patients with advanced or metastatic non-small cell lung cancer.

    Published in:
    Investigational New Drugs, 2016, v. 34, n. 5, p. 625, doi. 10.1007/s10637-016-0368-1
    By:
    • Scagliotti, Giorgio;
    • Kang, Jin;
    • Smith, David;
    • Rosenberg, Richard;
    • Park, Keunchil;
    • Kim, Sang-We;
    • Su, Wu-Chou;
    • Boyd, Thomas;
    • Richards, Donald;
    • Novello, Silvia;
    • Hynes, Scott;
    • Myrand, Scott;
    • Lin, Ji;
    • Smyth, Emily;
    • Wijayawardana, Sameera;
    • Lin, Aimee;
    • Pinder-Schenck, Mary
    Publication type:
    Article
    44
    45
    46
    47
    48

    Experience from Asian centers in a named-patient-use program for afatinib in patients with advanced non-small-cell lung cancer who had progressed following prior therapies, including patients with uncommon EGFR mutations.

    Published in:
    International Journal of Clinical Oncology, 2021, v. 26, n. 5, p. 841, doi. 10.1007/s10147-021-01869-0
    By:
    • Chang, Gee-Chen;
    • Lam, David Chi-Leung;
    • Tsai, Chun-Ming;
    • Chen, Yuh-Min;
    • Shih, Jin-Yuan;
    • Aggarwal, Shyam;
    • Wang, Shuhang;
    • Kim, Sang-We;
    • Kim, Young-Chul;
    • Wahid, Ibrahim;
    • Li, Rubi;
    • Lim, Darren Wan-Teck;
    • Sriuranpong, Virote;
    • Chan, Raymond Tsz-Tong;
    • Lorence, Robert M.;
    • Carriere, Philippe;
    • Raabe, Christina;
    • Cseh, Agnieszka;
    • Park, Keunchil
    Publication type:
    Article
    49

    Afatinib With Pembrolizumab for Treatment of Patients With Locally Advanced/Metastatic Squamous Cell Carcinoma of the Lung: The LUX-Lung IO/KEYNOTE 497 Study Protocol.

    Published in:
    2019
    By:
    • Levy, Benjamin;
    • Paz-Ares, Luis;
    • Bennouna, Jaafar;
    • Felip, Enriqueta;
    • Abreu, Delvys Rodríguez;
    • Isla, Dolores;
    • Barlesi, Fabrice;
    • Molinier, Olivier;
    • Madelaine, Jeannick;
    • Audigier-Valette, Clarisse;
    • Kim, Sang-We;
    • Kim, Hye Ryun;
    • Ozguroglu, Mustafa;
    • Erman, Mustafa;
    • Badin, Firas Benyamine;
    • Mekhail, Tarek M.;
    • Scheff, Ronald;
    • Chisamore, Michael J.;
    • Sadrolhefazi, Behbood;
    • Riess, Jonathan W.
    Publication type:
    journal article
    50